Sandoz sues to clear path for generic Prandin; Celgene board OKs $2B in buybacks;

@FiercePharma: Ranbaxy could waive Lipitor rights, let a rival generic to market...for a fee. If it can't get straight with FDA first. Article | Follow @FiercePharma

> Sandoz has asked a U.S. court to rule that its knock-off version of Novo Nordisk's diabetes drug Prandin will not infringe on the Danish company's patent. News

> Celgene's ($CELG) board authorized another $2 billion in stock buy-backs, adding to the $2.25 billion left from a previous program. Item

> Apricus Biosciences ($APRI) got the FDA nod for its Tolnaftate-D antifungal cream, its first product to be sold in the U.S. Story

> Swiss drugmaker Basilea Pharmaceutica posted a narrower net loss as a loss of contract revenue was partly offset by growing product sales. Article

> Merck's ($MRK) consumer products group is hunting for a global agency to handle its over-the-counter drug brands. Report

> Sagent Pharmaceuticals ($SGNT) launched its version of Norcuron, an injectable treatment for myasthenia gravis. News

> Valeant Pharmaceuticals ($VRX) said board member Michael Van Every has resigned for health reasons. Item

Biotech News

@FierceBiotech: Stanford investigators use "online dating" to match old drugs with new medical uses. Story | Follow @FierceBiotech

@JohnCFierce: Funny Icahn threat in conceding Forest bod vote. Imclone, Biogen, Genzyme all took time. (I'll be baa-a-a-ack.) More | Follow @JohnCFierce

@RyanMFierce: Hmm. Ireland-based academic says that private biotech spinoffs do better than those from universities Piece | Follow @RyanMFierce

@MaureenFierce: The other dark side of Merck's 13,000 layoffs: pharma's moving to greener pastures. Story | Follow @MaureenFierce

> GSK-owned Sirtris drug extends lives of obese mice. Story 

> Dendreon's fall trips up fellow biotechs on Wall Street. News 

> Roche targets 'good cholesterol' drug win where rivals failed. Story 

> Biotech venture to create 150 jobs in Florida. Article 

> Amgen drug shows it can 'improve heart function' in Ph2. News 

> China draws expats from U.S. to launch biotechs. Item

And Finally... One in 5 people seeking bankruptcy protection blames medical bills. Report

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.